Iñigo Les Bujanda

Position

Specialist physician in the Internal Medicine Department at the Autoimmune Diseases Unit of the Internal Medicine Service at the University Hospital of Navarra and principal investigator of the Inflammatory and Immune-Mediated Diseases Group at the Navarrabiomed-Public University of Navarra research centre, Institute of Health Research of Navarra

University Hospital of Navarra, Institute for Health Research of Navarra (IdiSNA)

Topics

immunotherapy, immunology, cancer

Study warns of risks associated with a type of cancer immunotherapy

cancer

Study warns of risks associated with a type of cancer immunotherapy

SMC Spain

Cancer patients receiving a type of immunotherapy known as Immune Checkpoint Inhibitor (ICI) have a higher risk of serious adverse events, such as aortic aneurysm rupture, interstitial lung disease, myositis and liver failure, according to a study published in PNAS. "Establishing formal contraindications for ICI users seems warranted," concludes the analysis, based on more than 290,000 cases from pharmacovigilance databases of the US Food and Drug Administration and the World Health Organisation.